According to Zacks, “BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company’s product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States. “
BBIO has been the topic of a number of other reports. UBS Group started coverage on BridgeBio Pharma in a research note on Tuesday, December 3rd. They set a reduce rating on the stock. Piper Jaffray Companies dropped coverage on BridgeBio Pharma in a report on Friday, October 18th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $40.13.
Shares of NASDAQ BBIO opened at $33.02 on Thursday. The firm’s 50-day moving average is $25.84. BridgeBio Pharma has a 1-year low of $17.61 and a 1-year high of $35.67. The company has a current ratio of 14.00, a quick ratio of 14.00 and a debt-to-equity ratio of 0.14.
BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.55) by $0.04. The company had revenue of $26.74 million for the quarter. Equities analysts anticipate that BridgeBio Pharma will post -3.08 EPS for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tiverton Asset Management LLC purchased a new position in shares of BridgeBio Pharma during the second quarter valued at approximately $76,000. Strs Ohio bought a new stake in BridgeBio Pharma during the third quarter worth $126,000. Point72 Hong Kong Ltd purchased a new stake in BridgeBio Pharma in the 2nd quarter valued at $255,000. Bank of Montreal Can purchased a new stake in BridgeBio Pharma in the 2nd quarter valued at $270,000. Finally, Metropolitan Life Insurance Co NY purchased a new stake in BridgeBio Pharma in the 3rd quarter valued at $233,000. Hedge funds and other institutional investors own 83.46% of the company’s stock.
About BridgeBio Pharma
BridgeBio Pharma, Inc finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology.
Recommended Story: What does a market perform rating mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.